Cargando…
Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin
BACKGROUND: The diagnosis of tuberculosis (TB) using smear microscopy has been based on testing two specimens: one spot and one early morning sputa. Recently, the World Health Organization (WHO) has recommended to replace, whenever possible, microscopy with GeneXpert® MTB/RIF performed on a single s...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454072/ https://www.ncbi.nlm.nih.gov/pubmed/34544371 http://dx.doi.org/10.1186/s12879-021-06676-6 |
_version_ | 1784570413100040192 |
---|---|
author | Massou, Faridath Fandohan, Merlin Wachinou, Ablo Prudence Agbla, Schadrac Christin Agodokpessi, Gildas Rigouts, Leen de Jong, Bouke Catherine Affolabi, Dissou |
author_facet | Massou, Faridath Fandohan, Merlin Wachinou, Ablo Prudence Agbla, Schadrac Christin Agodokpessi, Gildas Rigouts, Leen de Jong, Bouke Catherine Affolabi, Dissou |
author_sort | Massou, Faridath |
collection | PubMed |
description | BACKGROUND: The diagnosis of tuberculosis (TB) using smear microscopy has been based on testing two specimens: one spot and one early morning sputa. Recently, the World Health Organization (WHO) has recommended to replace, whenever possible, microscopy with GeneXpert® MTB/RIF performed on a single specimen. However, as the bacterial load is higher in early morning specimens than in spot specimens, one could expect lower sensitivity of GeneXpert® MTB/RIF performed only on spot specimens. In this study, we compared results of GeneXpert® MTB/RIF on spot specimens versus early morning specimens, under programmatic conditions in Cotonou, Benin. METHODS: From June to September 2018, all sputa received from presumptive TB patients at the Supranational Reference Laboratory for Tuberculosis of Cotonou were included in the study. From each patient, two specimens were collected (one spot and one early morning) and GeneXpert® MTB/RIF was performed on both specimens. RESULTS: In total, 886 participants were included in the study, of whom 737 provided both sputa and 149 (16.8%) gave only the spot specimen. For the 737 participants who provided both sputa, GeneXpert® MTB/RIF was positive for both specimens in 152 participants; for three participants GeneXpert® MTB/RIF was positive on spot specimen but negative on morning specimen while for another three, the test was positive on morning specimen but negative on spot specimen. The overall percentage of agreement was excellent (99.2%) with a positive and negative percent agreement greater than 98%. CONCLUSION: For TB diagnosis under programmatic conditions in Cotonou, GeneXpert® MTB/RIF in spot specimens gave similar results with the test in morning specimens. Performing GeneXpert® MTB/RIF in both specimens did not significantly increase the number of cases detected. To avoid losing patients from the diagnostic cascade, it is preferable to test sputa produced at the time of the first visit at the health center. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06676-6. |
format | Online Article Text |
id | pubmed-8454072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84540722021-09-21 Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin Massou, Faridath Fandohan, Merlin Wachinou, Ablo Prudence Agbla, Schadrac Christin Agodokpessi, Gildas Rigouts, Leen de Jong, Bouke Catherine Affolabi, Dissou BMC Infect Dis Research BACKGROUND: The diagnosis of tuberculosis (TB) using smear microscopy has been based on testing two specimens: one spot and one early morning sputa. Recently, the World Health Organization (WHO) has recommended to replace, whenever possible, microscopy with GeneXpert® MTB/RIF performed on a single specimen. However, as the bacterial load is higher in early morning specimens than in spot specimens, one could expect lower sensitivity of GeneXpert® MTB/RIF performed only on spot specimens. In this study, we compared results of GeneXpert® MTB/RIF on spot specimens versus early morning specimens, under programmatic conditions in Cotonou, Benin. METHODS: From June to September 2018, all sputa received from presumptive TB patients at the Supranational Reference Laboratory for Tuberculosis of Cotonou were included in the study. From each patient, two specimens were collected (one spot and one early morning) and GeneXpert® MTB/RIF was performed on both specimens. RESULTS: In total, 886 participants were included in the study, of whom 737 provided both sputa and 149 (16.8%) gave only the spot specimen. For the 737 participants who provided both sputa, GeneXpert® MTB/RIF was positive for both specimens in 152 participants; for three participants GeneXpert® MTB/RIF was positive on spot specimen but negative on morning specimen while for another three, the test was positive on morning specimen but negative on spot specimen. The overall percentage of agreement was excellent (99.2%) with a positive and negative percent agreement greater than 98%. CONCLUSION: For TB diagnosis under programmatic conditions in Cotonou, GeneXpert® MTB/RIF in spot specimens gave similar results with the test in morning specimens. Performing GeneXpert® MTB/RIF in both specimens did not significantly increase the number of cases detected. To avoid losing patients from the diagnostic cascade, it is preferable to test sputa produced at the time of the first visit at the health center. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06676-6. BioMed Central 2021-09-20 /pmc/articles/PMC8454072/ /pubmed/34544371 http://dx.doi.org/10.1186/s12879-021-06676-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Massou, Faridath Fandohan, Merlin Wachinou, Ablo Prudence Agbla, Schadrac Christin Agodokpessi, Gildas Rigouts, Leen de Jong, Bouke Catherine Affolabi, Dissou Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin |
title | Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin |
title_full | Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin |
title_fullStr | Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin |
title_full_unstemmed | Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin |
title_short | Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin |
title_sort | spot specimen testing with genexpert mtb/rif results compared to morning specimen in a programmatic setting in cotonou, benin |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454072/ https://www.ncbi.nlm.nih.gov/pubmed/34544371 http://dx.doi.org/10.1186/s12879-021-06676-6 |
work_keys_str_mv | AT massoufaridath spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin AT fandohanmerlin spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin AT wachinouabloprudence spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin AT agblaschadracchristin spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin AT agodokpessigildas spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin AT rigoutsleen spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin AT dejongboukecatherine spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin AT affolabidissou spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin |